Deoxycholic Acid Obesity Drugs Market Report 2026

Deoxycholic Acid Obesity Drugs Market Overview

• Deoxycholic Acid Obesity Drugs market size has reached to $0.5 billion in 2025 • Expected to grow to $0.97 billion in 2030 at a compound annual growth rate (CAGR) of 14.1% • Growth Driver: Rising Obesity Rates Driving Demand For The Market Due To Increasing Prevalence Of Overweight Populations • Market Trend: Patient-Centric Solutions Enhance At-Home Diagnostics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Deoxycholic Acid Obesity Drugs Market?

Deoxycholic acid obesity drugs are pharmaceutical products containing deoxycholic acid, a naturally occurring bile acid, designed to break down and eliminate localized fat deposits. They are mainly used in non-surgical fat reduction procedures, targeting areas such as the chin, abdomen, and other resistant fat zones. The main types of deoxycholic acid obesity drugs are ATX-101 (deoxycholic acid injection, or Kybella or Belkyra), experimental or compounded deoxycholic acid formulations, combination therapies, and oral deoxycholic acid products. ATX-101 (Deoxycholic Acid Injection, or Kybella, or Belkyra) refers to the commercially approved injectable formulations of deoxycholic acid used for targeted fat reduction. They are available in several formulations, such as injectable and topical options, and are distributed through various distribution channels, including direct sales, retail pharmacies, and online pharmacies. These drugs are applied for multiple applications, such as submental fat reduction, abdominal fat reduction, thighs, arms, and flanks, lipomas, localized fat, and cellulite management, and are primarily utilized by various end-users, including aesthetic clinics, dermatology clinics, plastic surgery centers, hospitals, and administration.

What Is The Deoxycholic Acid Obesity Drugs Market Growth Forecast?

The deoxycholic acid obesity drugs market size is expected to see rapid growth in the next few years. It will grow to $0.97 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to increasing demand for personalized aesthetic treatments, expansion of combination aesthetic protocols, rising focus on body contouring procedures, growing investments in aesthetic drug innovation, increasing penetration in emerging markets. Major trends in the forecast period include increasing adoption of non-surgical fat reduction procedures, rising demand for injectable aesthetic treatments, growing development of combination lipolytic therapies, expansion of clinic-based body contouring services, enhanced focus on patient-specific aesthetic outcomes.

Global Deoxycholic Acid Obesity Drugs Market Segmentation

1) By Drug Type: ATX-101 (Deoxycholic Acid Injection Or Kybella Or Belkyra), Experimental Or Compounded Deoxycholic Acid Formulations, Combination Therapies, Oral Deoxycholic Acid Products 2) By Formulation: Injectable, Topical 3) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies 4) By Application: Submental Fat Reduction, Abdominal Fat Reduction, Thighs Arms And Flanks, Lipomas And Localized Fat, Cellulite Management 5) By End-User: Aesthetic Clinics, Dermatology Clinics, Plastic Surgery Centers, Hospitals, Home Administration Subsegments: 1) By ATX-101 (Deoxycholic Acid Injection or Kybella or Belkyra): Standard Injectable, High-Purity Formulations, Combination Injection Therapies 2) By Experimental Or Compounded Deoxycholic Acid Formulation: Clinical Trial Formulations, Compounded Customized Formulations 3) By Combination Therapies: Deoxycholic Acid + Lipolytic Agents, Deoxycholic Acid + Enzyme Therapy 4) By Oral Deoxycholic Acid Products: Capsules, Tablets, Liquid Formulations

What Are The Drivers Of The Deoxycholic Acid Obesity Drugs Market?

The rising obesity rates are expected to propel the growth of the deoxycholic acid obesity drug market going forward. Obesity rates refer to the percentage of a population classified as overweight or obese based on body mass index (BMI). Increasing obesity rates are driven by poor dietary habits, such as high intake of processed foods and sugary drinks, resulting to excess calorie storage as body fat. Deoxycholic acid obesity drugs help reduce obesity rates by breaking down and eliminating excess fat cells, leading to targeted fat reduction and improved body contour. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, from 2023 to 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64.0% in 2022 to 2023 Therefore, the rising obesity rates are driving the growth of the deoxycholic acid obesity drug industry. The rising demand for non-surgical body contouring options is expected to propel the growth of the deoxycholic acid obesity drug market going forward. Non-surgical body contouring options refer to non-invasive or minimally invasive treatments that use technologies such as cryolipolysis, ultrasound, radiofrequency, or lasers to reduce fat, tighten skin, and reshape the body without surgery or downtime. The demand for non-surgical body contouring is rising as consumers prefer safer, minimally invasive alternatives to traditional cosmetic surgery that provide effective fat reduction and skin tightening with minimal pain, lower risk, and little or no recovery time. Deoxycholic acid obesity drugs help in non-surgical body contouring by breaking down and absorbing localized fat cells when injected into targeted areas, resulting to a reduction in stubborn fat pockets and improved body shape without the need for invasive surgery. For instance, in June 2024, according to the International Society of Aesthetic Plastic Surgery, a US-based professional organization, in 2023, botulinum toxin continued to be the leading non-surgical procedure for all genders and age groups, with plastic surgeons performing 8.8 million treatments globally, while hyaluronic acid procedures rose 29% to reach 5.5 million. Therefore, the rising demand for non-surgical body contouring options is driving the growth of the deoxycholic acid obesity drugs industry.

Key Players In The Global Deoxycholic Acid Obesity Drugs Market

Major companies operating in the deoxycholic acid obesity drugs market are AbbVie Inc., Cipla Ltd., Glenmark Life Sciences Limited, Curia Global Inc., Daewoong Pharmaceutical Co. Ltd., Actylis, ICE Pharma, Cayman Chemical Company, Nacalai Tesque Inc., Sichuan Huiyu Pharmaceutical, Conscientia Industrial, Manus Aktteva Biopharma LLP, Jeevan Chemicals & Pharmaceuticals, Anhui Chem-Bright Bioengineering Co. Ltd., GlpBio Technology LLC, Legere Pharmaceuticals, Otto Chemie Pvt. Ltd., BOC Sciences, Guangzhou Green Cross Pharmaceutical, Prodotti Chimici e Alimentari S.P.A

Global Deoxycholic Acid Obesity Drugs Market Trends and Insights

Major companies operating in the deoxycholic acid obesity drug market are focusing on developing advanced products, such as injectable deoxycholic acid obesity drugs, to enhance treatment efficacy and improve patient outcomes. Injectable deoxycholic acid obesity drugs use deoxycholic acid, which is a substance that breaks down fat cells, and are given as an injection to specifically target and reduce fat in certain areas. For instance, in March 2024, LG Chem Ltd., a South Korea-based chemicals company, introduced Bellacholine for the reduction of submental fat. It is a nonsurgical injection designed to reduce moderate to severe submental fat (double chin) by safely destroying fat cells using deoxycholic acid. It offers advantages such as body-compatible pH, minimal sedimentation, and promotion of skin elasticity through collagen synthesis.

Regional Insights

North America was the largest region in the deoxycholic acid obesity drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Deoxycholic Acid Obesity Drugs Market?

The deoxycholic acid obesity drugs market consists of sales of injection lipolysis with bile acid derivatives, investigational and preclinical agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Deoxycholic Acid Obesity Drugs Market Report 2026?

The deoxycholic acid obesity drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the deoxycholic acid obesity drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.